Supers, Inc., an artificial intelligence-based medical software company, announced that it has signed a business agreement with global non-clinical CRO specialist CoastemChemOn, Inc. to establish a digital pathology-based non-clinical pathology interpretation verification support system and enhance AI-based new drug development support services.
Preclinical toxicology pathology interpretation has traditionally relied heavily on visual assessment by experienced pathologists. This has consistently led to limitations such as slow analysis speed, discrepancies in interpretation results, and the cost and time burden of repeat analyses. This agreement aims to improve these structural issues and enhance the overall efficiency of nonclinical trials by leveraging digital pathology and AI technologies.
Through this agreement, the two companies will jointly establish a non-clinical research support environment that integrates digital pathology technology and AI. They will also gradually implement validation and technological advancements to improve the efficiency of pathology interpretation and data utilization. This will reduce repetitive and time-consuming tasks associated with preclinical toxicology pathology analysis, while simultaneously increasing the speed and reliability of research decision-making.
Superspas will enhance the precision and consistency of nonclinical pathology data analysis through Innisview, an AI-based morphometric solution, and the Innisscope platform, which utilizes a digital pathology-based service model. By linking pathology images and experimental data, Superspas aims to transform the entire preclinical toxicology pathology analysis process into a more systematic and intelligent workflow.
Based on its years of experience conducting non-clinical trials and its expertise in CRO operations, CoastemChemOn plans to focus on creating a research environment that streamlines trial costs and timelines and enhances data utilization by applying Superpass's AI pathology analysis service to the non-clinical trial process. Specifically, the collaboration will advance the digital pathology-based pathology interpretation support system to enhance the reproducibility and usability of non-clinical data.
CEO Yong-Hwan Kim of SuperSpeed said that by applying AI-based digital pathology interpretation services to non-clinical CRO sites, he expects to be able to improve the bottleneck problem of pathology interpretation that has been repeated in the pre-clinical research process, and that he will focus on improving the cost and period efficiency of non-clinical trials and building a data-based analysis environment.
Song Si-hwan, President of the Non-Clinical CRO Division at KoastemChemOn, said, “We expect to increase the efficiency of the trial process and the reliability of results by establishing a non-clinical research support system that combines digital pathology and AI technology,” and added, “We hope that this collaboration will lead to strengthening the competitiveness of domestic non-clinical CRO services.”
- See more related articles
You must be logged in to post a comment.